MASH treatment

London, UK, September 3, 2026 Tangram Therapeutics announced that its investigational MASH treatment TGM-312 has progressed into Part B...

MISSISSAUGA, Ontario — December 15, 2025 — Novo Nordisk Canada Inc. announced that Health Canada has granted conditional marketing...